About Genomenon
Genomenon is a precision medicine and genomics company that transforms biomedical literature into actionable real-world evidence for biopharma companies and clinical diagnostic laboratories. The company addresses a critical challenge in genomics: the evidence needed to recognize diseases, classify genetic variants, and reach patients exists in published literature, but finding it across 11.2 million full-text articles and 3.7 million supplemental datasets is extraordinarily difficult. Genomenon's AI-powered platform reads every word of millions of articles and data sources, which scientists then analyze, structure, and curate to deliver traceable, regulatory-grade evidence at scale. For biopharma, Genomenon provides custom real-world evidence builds that support broader drug labels, identify more eligible patients, and create programs defensible to regulators. For clinical labs, the company offers Mastermind for germline variant interpretation and the Cancer Knowledgebase (CKB) for somatic variant interpretation, enabling faster case sign-outs, fewer variants of uncertain significance (VUS), and more confident diagnoses. The company also provides clinical diagnostic services including variant curation, interpretation, workflow optimization, and regulatory compliance support. Genomenon's three-step process—identify, structure, and curate—transforms hidden evidence into confident decisions, serving leading health systems, research institutions, and pharmaceutical companies globally.
Mission & Story
Mission
Every Patient Deserves Complete Evidence
Clinical Focus
Medical conditions and clinical areas addressed by Genomenon.
Who It Serves
Milestones & Awards
Recent Milestones
Curated over 1.7 million variants with 90% validation success. Scaled curation teams from 10 to 36 curators in 12 months for clients. Reduced patient backlogs by 50% TAT.
Key Partnerships
Social & Media
Latest Updates
Company Details
- Headquarters
- Ann Arbor, MI, USA
Work here?
Claim this listing to update company information and connect with our audience.
Claim This ListingOfficial Sources
Similar Companies in this Market
View all 60 →
23andMe
23andMe uses AI to analyze genetic data and provide personalized health summaries, risk assessments, and wellness recommendations based on genomic insights.
2bPrecise
AI-powered precision medicine platform for personalized treatment recommendations and genomic analysis.
ACT Genomics
AI-powered genomic analysis platform for precision medicine and personalized treatment recommendations.
Adaptive Biotechnologies
Adaptive Biotechnologies uses AI and machine learning to decode the immune system and identify disease-specific immune signatures for diagnosis and personalized treatment.
Ambry Genetics
Ambry Genetics is a leading clinical genetic testing laboratory specializing in hereditary cancer, rare disease, cardiology, and neurology testing. The company provides advanced genetic testing solutions with paired DNA/RNA analysis and comprehensive patient support programs.
Ataraxis
Ataraxis develops AI-native precision medicine tools that predict patient outcomes and treatment response in oncology. Their flagship product, Ataraxis Breast, provides clinically validated prognostic and predictive tests for breast cancer using multi-modal AI analysis of pathology images and clinical data.
Avenda Health
Avenda Health develops Unfold AI, an FDA-cleared artificial intelligence platform that creates 3D cancer estimation maps for prostate cancer. The technology analyzes standard-of-care data (MRI, biopsy, pathology, PSA) to visualize cancer location and extent, helping physicians make more informed treatment decisions and improve patient outcomes.
Base Genomics
Base Genomics appears to be a company in the Precision Medicine & Genomics space, but the scraped website content is empty or inaccessible, preventing detailed analysis of their offerings and target market.
Data Accuracy Notice: Company information on HealthAI Central is compiled from public sources and updated regularly. While we strive for accuracy, details such as funding figures, employee counts, and product offerings may change. We recommend verifying critical information directly with the company before making business decisions.